Viking Therapeutics, Inc.
VKTX
$35.63
$0.160.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 31.03% | -40.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 67.14% | 32.17% | |||
| Operating Income | -67.14% | -32.17% | |||
| Income Before Tax | -73.66% | -38.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -73.66% | -38.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -73.66% | -38.48% | |||
| EBIT | -67.14% | -32.17% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -71.09% | -38.24% | |||
| Normalized Basic EPS | -71.14% | -38.26% | |||
| EPS Diluted | -71.09% | -38.24% | |||
| Normalized Diluted EPS | -71.14% | -38.26% | |||
| Average Basic Shares Outstanding | 1.50% | 0.17% | |||
| Average Diluted Shares Outstanding | 1.50% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||